Berenberg Bank Lowers Dr. Martens (LON:DOCS) Price Target to GBX 110

Dr. Martens (LON:DOCS) had its target price dropped by investment analysts at Berenberg Bank from GBX 114 to GBX 110 in a research report issued on Tuesday,Digital Look reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price target suggests a potential upside of 65.17% from the stock’s previous close.

Separately, Royal Bank Of Canada reissued a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 110.

Dr. Martens Stock Performance

DOCS opened at GBX 66.60 on Tuesday. Dr. Martens has a 12-month low of GBX 53.05 and a 12-month high of GBX 100.87. The stock has a market cap of £644.15 million, a price-to-earnings ratio of 39.18, a PEG ratio of 6.40 and a beta of 0.22. The business has a 50 day moving average of GBX 63.94 and a 200-day moving average of GBX 71.49. The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 120.66.

Insiders Place Their Bets

In related news, insider Ije Nwokori sold 204,051 shares of Dr. Martens stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66. Over the last ninety days, insiders purchased 930 shares of company stock worth $59,984. Company insiders own 2.81% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.